Saltoro Capital’s BridgeBio Pharma BBIO Stock Holding History

Saltoro Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,668	Closed	-$226K	–	102
2021 Q1	$226K	Buy	+3,668	New	+$240K	0.06%	85

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Saltoro Capital's BBIO Position: Q2 2021 in Review

Saltoro Capital sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 3,668 shares — an estimated $226K sold.

Saltoro Capital first reported a position in BBIO in Q1 2021 and held it in 1 quarter. The position peaked at $226K in Q1 2021. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

Saltoro Capital reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
Saltoro Capital sold 3,668 BridgeBio Pharma shares in Q2 2021, an estimated $226K.
Saltoro Capital first reported a position in BridgeBio Pharma in Q1 2021 and held it in 1 quarter.
Saltoro Capital's BridgeBio Pharma position peaked at $226K in Q1 2021.
200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Saltoro Capital's 13F filing for Q2 2021, filed 12 Aug 2021.